Details for Patent: 7,439,342

Title:	Thrombopoietin mimetics
Abstract:	Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Inventor(s):	Duffy; Kevin J. (Collegeville, PA), Luengo; Juan I. (Collegeville, PA)
Assignee:	Smith Kline Beecham Corp. (Philadelphia, PA)
Filing Date:	Jan 08, 2007
Application Number:	11/650,688
Claims:	1. A compound represented by the following formula: ##STR00015## wherein AR is a polycyclic aromatic ring containing 3 to 16 carbon atoms and containing one or more heteroatoms, provided that when the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring contains at least one heteroatom, and optionally substituted with one or more substituents selected from the group consisting of: alkyl, trifluoromethyl and hydroxy; and R.sup.1 and R.sup.2 are independently selected from hydrogen and alkyl, provided that R.sup.1 and R.sup.2 are not both hydrogen; or a pharmaceutically acceptable salt thereof. 2. A compound according to claim 1 wherein: the AR contains one or two heteroatoms and is substituted with one or more substituents selected from the group consisting of: alkyl, trifluoromethyl and hydroxy; and R.sup.1 and R.sup.2 are independently selected from hydrogen and alkyl, provided that R.sup.1 and R.sup.2 are not both hydrogen; or a pharmaceutically acceptable salt thereof. 3. A compound according to claim 2 wherein: the AR is substituted with one or two substituents selected from the group consisting of: alkyl, trifluoromethyl and hydroxy; and R.sup.1 and R.sup.2 are independently selected from hydrogen and alkyl, provided that R.sup.1 and R.sup.2 are not both hydrogen; or a pharmaceutically acceptable salt thereof. 4. A compound according to claim 3 wherein: R.sup.1 and R.sup.2 are both methyl; or a pharmaceutically acceptable salt thereof. 5. A compound according to claim 3 wherein: one of R.sup.1 and R.sup.2 is hydrogen and the other is propyl; or a pharmaceutically acceptable salt thereof. 6. A pharmaceutical composition which comprises a compound of claim 1 and a pharmaceutically acceptable carrier. 7. A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and an effective amount of the compound of claim 1, which process comprises bringing said compound into association with the pharmaceutically acceptable carrier or diluent. 8. A pharmaceutical composition which comprises a compound of claim 2 and a pharmaceutically acceptable carrier. 9. A pharmaceutical composition which comprises a compound of claim 3 and a pharmaceutically acceptable carrier. 10. A pharmaceutical composition which comprises a compound of claim 4 and a pharmaceutically acceptable carrier. 11. A pharmaceutical composition which comprises a compound of claim 5 and a pharmaceutically acceptable carrier.